Literature DB >> 27407360

CORRELATIONSHIP OF CATHEPSIN D AND TOPOISOMERASE II ALPHA WITH NUCLEAR GRADING IN BREAST CANCERS.

Prabal Deb1, G U Deshpande2.   

Abstract

56 cases of infiltrating duct carcinoma of the breast were studied for the expression of cathepsin D and topoisomerase II alpha. The results were correlated with the morphological differentiation, as determined by the Nottingham's modification of the Bloom-Richardson system. Cathepsin D posltivity in tumour cells and stromal cells was seen in 44.6% and 55.4% cases respectively, whereas topoisomerase II alpha positivity was seen in 33.9% cases. In grade II tumours cathepsin D in tumour cells and stromal cells was 44.4% and 47.2% respectively, as compared to 27.8% posltivity for topoisomerase II alpha. The corresponding figures for grade III tumours were 50.0%, 79.6% and 64.3 % respectively. As grade I comprised only 3 cases no statistical correlation could be observed. It is evident that with increase in tumour grade there is a statistical increase in expression of cathepsin D, a lysosomal acidle protease-implicated in the process of tumour invasion and metastasis, and of topoisomerase II alpha, a marker of rapid cell proliferation and aneuploidy.

Entities:  

Keywords:  Breast carcinoma; Cathepsin D; Grading; Prognosis; Topoisomerase II alpha

Year:  2011        PMID: 27407360      PMCID: PMC4923918          DOI: 10.1016/S0377-1237(02)80047-8

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  13 in total

1.  Expression and refolding of recombinant human fibroblast procathepsin D.

Authors:  G E Conner; J A Udey
Journal:  DNA Cell Biol       Date:  1990 Jan-Feb       Impact factor: 3.311

Review 2.  Status of breast cancer prognostication based on histopathologic data.

Authors:  J F Simpson; D L Page
Journal:  Am J Clin Pathol       Date:  1994-10       Impact factor: 2.493

Review 3.  Cathepsin D in the malignant progression of neoplastic diseases (review).

Authors:  G Leto; N Gebbia; L Rausa; F M Tumminello
Journal:  Anticancer Res       Date:  1992 Jan-Feb       Impact factor: 2.480

4.  Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer.

Authors:  T A Järvinen; J Kononen; M Pelto-Huikko; J Isola
Journal:  Am J Pathol       Date:  1996-06       Impact factor: 4.307

5.  Cathepsin D in host stromal cells, but not in tumor cells, is associated with aggressive behavior in node-negative breast cancer.

Authors:  M Nadji; M Fresno; M Nassiri; G Conner; A Herrero; A R Morales
Journal:  Hum Pathol       Date:  1996-09       Impact factor: 3.466

6.  In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells.

Authors:  P Briozzo; M Morisset; F Capony; C Rougeot; H Rochefort
Journal:  Cancer Res       Date:  1988-07-01       Impact factor: 12.701

7.  Hormonal regulation of cathepsin D following transfection of the estrogen or progesterone receptor into three sex steroid hormone resistant cancer cell lines.

Authors:  I Touitou; F Vignon; V Cavailles; H Rochefort
Journal:  J Steroid Biochem Mol Biol       Date:  1991       Impact factor: 4.292

8.  Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively.

Authors:  K B Tan; T E Dorman; K M Falls; T D Chung; C K Mirabelli; S T Crooke; J Mao
Journal:  Cancer Res       Date:  1992-01-01       Impact factor: 12.701

9.  Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.

Authors:  P Hellemans; P A van Dam; M Geyskens; A T van Oosterom; P Buytaert; E Van Marck
Journal:  J Clin Pathol       Date:  1995-02       Impact factor: 3.411

Review 10.  Vinorelbine and the topoisomerase 1 inhibitors: current and potential roles in breast cancer chemotherapy.

Authors:  S O'Reilly; M J Kennedy; E K Rowinsky; R C Donehower
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.